Overview

Study of Salirasib to Treat Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Salirasib is effective to shrink or prevent the growth of the tumors associated with non-small cell lung cancer in both patients who are newly diagnosed or have recurrent disease.
Phase:
Phase 2
Details
Lead Sponsor:
Concordia Pharmaceuticals, Inc
Treatments:
Farnesylthiosalicylic acid
Salicylates